Adial Pharmaceuticals Inc
NASDAQ:ADIL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Adial Pharmaceuticals Inc
Other Long-Term Assets
Adial Pharmaceuticals Inc
Other Long-Term Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Long-Term Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Adial Pharmaceuticals Inc
NASDAQ:ADIL
|
Other Long-Term Assets
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Other Long-Term Assets
$19.3B
|
CAGR 3-Years
3%
|
CAGR 5-Years
8%
|
CAGR 10-Years
7%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Other Long-Term Assets
$8.2B
|
CAGR 3-Years
42%
|
CAGR 5-Years
20%
|
CAGR 10-Years
8%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Other Long-Term Assets
$19.3B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
28%
|
CAGR 10-Years
14%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Other Long-Term Assets
$17.8B
|
CAGR 3-Years
30%
|
CAGR 5-Years
13%
|
CAGR 10-Years
11%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Other Long-Term Assets
$17B
|
CAGR 3-Years
33%
|
CAGR 5-Years
22%
|
CAGR 10-Years
23%
|
|
Adial Pharmaceuticals Inc
Glance View
Adial Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which focuses on the treatment of alcohol use disorder. The company is headquartered in Charlottesville, Virginia and currently employs 16 full-time employees. The company went IPO on 2018-07-27. The firm is focused on the development of therapeutics for the treatment or prevention of addiction and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) AD04 is investigated in the Company’s ONWARD pivotal Phase III clinical trial for the treatment of AUD in subjects with certain target genotypes, which are to be identified using the Company’s proprietary companion diagnostic genetic test. AD04 is used for the treatment of other addictive disorders, such as Opioid Use Disorder, obesity, smoking, and other drug addictions. The firm is also developing adenosine analogs for the treatment of pain and other disorders through its wholly owned subsidiary, Purnovate, Inc.
